Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

The goal of this clinical trial is to determine the benefit of relugolix 40 milligrams (mg) once a day compared with placebo in heavy menstrual bleeding associated with uterine fibroids. The main question\[s\] it aims to answer are: * the benefit of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids * the safety of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids

NCT Number	NCT06671548
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Heavy Menstrual Bleeding, Uterine Fibroids
Enrollment	120 participants
Start Date	2024-01-15
Primary Completion	2026-11-12 (estimated)
Study Completion	2027-01-07 (estimated)
Updated on ClinicalTrials.gov	2026-02-02